# Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

Study · id `cardio:ct-nct06643130` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06643130](<https://clinicaltrials.gov/study/NCT06643130>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06643130

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 162 participants.

## Technical summary

Registry record NCT06643130. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-02 (actual); primary completion 2026-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 162 participants (planned count; ClinicalTrials.gov record NCT06643130, source copy `cardio:ctgov-nct06643130-2025-09-09`, retrieved 2026-10-26)
- Started: 2024-12-02 (actual) (ClinicalTrials.gov record NCT06643130, source copy `cardio:ctgov-nct06643130-2025-09-09`, retrieved 2026-10-26)
- Primary completion: 2026-04 (anticipated) (ClinicalTrials.gov record NCT06643130, source copy `cardio:ctgov-nct06643130-2025-09-09`, retrieved 2026-10-26)
- Completion: 2026-04 (anticipated) (ClinicalTrials.gov record NCT06643130, source copy `cardio:ctgov-nct06643130-2025-09-09`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06643130, source copy `cardio:ctgov-nct06643130-2025-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06643130-2025-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
- Condition: Hypertension
- Condition: Dyslipidemia
- Intervention (Drug): JW0104+C2402
- Intervention (Drug): JW0104+C2403
- Intervention (Drug): C2402
- Lead sponsor: JW Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: JW Pharmaceutical (`cardio:org-jw-pharmaceutical`)

## Provenance

Content hash: 53dad54b564d19cf6ce068bb3c73a12c69f4d1aa036c93fd9988a40484664770
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
